請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27527完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 饒宇東(Yu-Tung Yao) | |
| dc.contributor.author | Chia-Tung Shun | en |
| dc.contributor.author | 孫家棟 | zh_TW |
| dc.date.accessioned | 2021-06-12T18:08:25Z | - |
| dc.date.available | 2008-02-19 | |
| dc.date.copyright | 2008-02-19 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-12-12 | |
| dc.identifier.citation | 參考文獻
1.http://www.doh.gov/ 2.Houghton J, and Wang TC. Tumors of the stomach. In Sleisenger and Fordtran’s Gastrointestinal and Liver disease. Feldman M, Freidman LS, and Brandt LJ editors. Saunder Elsevier, Philaddphia, PA. 2006;1139-1170 3.Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49. 4.Sayegh, ME, Santo, T., Dexter, S., Katai, H., Fukagawa, T., and Sasako, M. TNM and Japanese staging systems for gastric cancer :how do they coexist ? Gastric Cancer 2004; 7:140-8. 5.Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;I:1311-4. 6.Marshall BJ, Rocye H, Annear D1, Gwodwin CS, Pearman JW, Warren JR and Armstrony JA : Original Isolation of Campylobacter pylori from human gastric mucosa. Microbios. Lett 1984; 25:83-8. 7.Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. Eur. J. Gastroen Hepatology. 1994; 6 ( Suppl 1):S79-83. 8.Antonioli DA. Precursors of gastric carcinoma: a critical review with a brief description of early (curable) gastric cancer. Human Pathol. 1994:25(10):994- 1005. 9.Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer. 1995;75:1410-1417. 10.Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Human Pathol. 1994;25(10):968-981. 11.Japanese Research Society for gastric cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg. 1981;11(2):127. 12.Spicer SS. Diamine methods for differentiating mucosubstances histochemically. J. Histochem Cytochem. 1965;3:211-34. 13.Hsu SM, Raine L, Fanger H. Use of avidin-biotin- peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;75:734. 14.Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br. J. Cancer. 1993; 67:589-593. 15.Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995; 76:720-6. 16.Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992;84:1109-14. 17.Remikos Y, Tominaga O, Hammel P, Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992;66:758-64. 18.Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Human Pathol. 1993;24:584-9. 19.Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992;50:859-62. 20.Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer. 1992; 66:558-62. 21.Fuchs CS, Mayer RJ.Gastric carcinoma.N Engl J Med. 1995;333:32-41. 22.Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11-21. 23.Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology. 2001;121:1339-47. 24.Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol. 2002;15:973-81. 25.Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 1999;94:451-5. 26.Levine AJ. The p53 tumor-suppressor gene. N Engl J Med. 1992;326:1350-2. 27.Nigro JM, Baker SJ, Preisinger AC, Jessup M, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins F, weton A, Modalli R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-8. 28.Kinzler KW, Vogelstein B. Cancer therapy meets p53.N Engl J Med. 1994; 331:49-50. 29.Bálint É, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer. 2001;85:1813-23. 30.Thierry S. P53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777-88. 31.Shepherd T, Tolbert D, Benedetti J, Macdonald J, Stemmermann G, Wiest J, Devoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C. Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology. 2000; 118: 1039-44. 32.Bochner BH, Esrig D, Groshen S, Dickinson M, Weidner N, Nichols PW, Skinner DG, Cote RJ. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clin Cancer Res. 1997 ;3:1615-22 33.Jänne PA, Mayer RJ. Primary care: chemoprevention of colorectal cancer. N Engl J Med. 2000 ; 342:1960-8. 34.Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joesun H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62:632-5. 35.Kawabe A, Shimada Y, Uchida S, Maeda M, Sato F, Itami A, Imamura M. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology. 2002;62:46-54. 36.Harris CC, Hollstein M. Medical Progress: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-27 37.Yamagata R, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol. 2002;14:359-63. 38.Sunayama K, Kono H, Nakamura T, Kashiwabara H, Shoji T, Tsuneyoshi T, Nakamura S. The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice. Carcinogenesis. 2002;23:1351-9. 39.Sakuma K, Fujimori T, Hirabayashi K, Terano A. Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol. 1999 ;34:189-94. 40.Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ. Association between cyclooxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84:335-9. 41.Rajnakova A, Moochhala S, Goh PM, Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett. 2001;172:177-85. 42.Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis. 1999; 20:2195-208. 43.Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, Polak JM, Knight S, Talbot IC. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol. 1999;187:295-301. 44.Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276-80. 45.Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK. Cyclooxygenase-2 expression in Helicobacter pylori- associated premalignant and malignant gastric lesions. : Am J Pathol. 2000;157:729-35. 46.Romano M, Ricci V, Memoli A, Tuccillo C, Di Popolo A, Sommi P, Acquaviva AM, Del Vecchio Blanco C, Bruni CB, Zarrilli R. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem. 1998;273:28560-3. 47.Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 1999;116:1319-29. 48.McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:1218-23. 49.Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999;274:10911-5. 50.Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol. 1996;23:307-15. 51.Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res. 2000;20:751-62. 52.David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A. 1966;56:72-7. 53.Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153:80-2. 54.Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J. 1996; 10:1607-13. 55.Lue H, Kleemann R, Calandra T, Roger T, Berhager J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 2002;4:449-60. 56.Meyer-Siegler K, Hudson PB. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 1996;48:448-52. 57.Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun. 1999;264:751-8. 58.Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000;89:334-41. 59.Del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, Cintorino M. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate. 2000;45:51-7. 60.Akbar SM, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, Michitaka K, Horiike N, Onji M. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 2001;171:125-32. 61.Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res. 2002;93:389-96. 62.Munaut C, Boniver J, Foidart JM, Deprez M. Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol. 2002; 28:452-60. 63.Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res. 2002;8 :3755-60. 64.Pyle ME, Korbonits M, Gueorguiev M, Jordan S, Kola B, Morris DG, Meinhardt A, Powell MP, Claret FX, Zhang Q, Metz C, Bucala R, Grossman AB. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol. 2003;176:103-10. 65.Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schuring MP, Salmon I, Gabius HJ, Pector JC, Kiss R. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol. 2003;16:491-504. 66.Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375-82. 67.Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med. 1998;4:707-14. 68.Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999;5:181-91. 69.Ogawa H, Nishihira J, Sato Y, Kondo M, Takahashi N, Oshima T, Todo S. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine. 2000;12:309- 14. 70.White ES, Stroma SR, Wys NL, Arenberg DA. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol. 2001; 166:7549-55. 71.Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biol. 2002; 23:123-9. 72.White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9:853- 60. 73.Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003;107:22-9. 74.Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel J. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol. 2003; 162:11-7. 75.Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semi. Cancer Biol. 2000;10:359-66 76.Nishihira J, Ishiboshi T, Fukushima T, Sun B, Sato Y, Todo S. Macrophage migration inhibitory factor (MIF): its’ potential role in tumor growth and tumor- associated angiogenesis. Ann N. Y. Acd. Sci. 2003;995:171-82 77.Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Hass R, Moll U, Muller W, Bucala R. The p53 dependent effects of Macrophage migration inhibitory factor revealed by gene targeting. Proc. Nate. Acad. Sci. USA. 2003;100:9354-9 78.Maase C, Eckmann L, Paesold G, Kim HS, Kagnoff MT. Ubiquitous production of macrophage migration inhibitory factor by gastric and intestinal epithelium. Gastroenterology. 2002;122:667-80 79.Haung XR, ChunHui CW, Chen YX, Wong BC, Fung PC, Mets C, Cho CH, Hui WM, Bucala R, Lam SK, Lan HY. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology. 2001;121:619-30 80.Wu MS, Shun CT, Wu CC, Hsu TY, Lin MC, Chang MC, Wang HP, Lin JT. Epstein-Barr-Virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology. 2000;118:1031-8. 81.Huang SP, Wu MS, Shun CT, Wang HP, Lin JT. Tumor angiogenesis increases with nuclear p53 accumulation in gastric carcinomas. Hepatogastroenterology. 2002; 49:1453-6 82.Frenetle PS, Wagner DD. Adhesion molecules .N Engl J Med. 1996;334:1526-9. 83.Edelman GM, Crossin KL. Cell adhesion molecules: implications for a molecular histology. Annu Rev Biochem. 1991;60:155-90. 84.Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 1989 ;108:2435-47 85.Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem. 1990;59:237-52. 86.Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198:11-26. 87.Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E- cadherin mediated adhesion system in cancer cells. Cancer. 1996;77(8 Suppl):1605-13. 88.Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107-19. 89.Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, Takeichi M, Abe O. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 1989;49:2128-33. 90.Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M, Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol. 1991;139:17-23. 91.Lin JT, Wang JT, Wang TH, Wu MS, Chen CJ. Helicobacter pylori infection in early and advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese patients. Hepatogastroenterology. 1993;40:596-9. 92.Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funke I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993;53:1690-5. 93.Shino Y, Watanabe A, Yamada Y, Tanase M, Yamada T, Matsuda M, Yamashita J, Tatsumi M, Miwa T, Nakano H. Clinicopathologic evaluation of immunohistochemical E- cadherin expression in human gastric carcinomas. Cancer. 1995;76:2193-201. 94.Shimoyama Y, Hirohashi S. Expression of E- and P- cadherin in gastric carcinomas. Cancer Res. 1991;51:2185-92. 95.Matsuura K. Kawanishi J. Fujii S. Imamura M. Hirano S. Takeichi M. Niitsu Y. Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid. Br. J. Cancer. 1992;66(6):1122-30 96.Oka H, Shiozaki H, Kobayashi K, Tahara H, Tamura S, Miyata M, Doki Y, Iihara K, Matsuyoshi N, Hirano S, Immunohistochemical evaluation of E-cadherin adhesion molecule expression in human gastric cancer. Virchows Archir (A) 1992;421:149-56 97.Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E- cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997;112:46-54. 98.Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994;54:3929-33. 99.Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol. 1994;174:101-9. 100.Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol. 1994;125:1327-40. 101.Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84:345-57. 102.Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997;13:119-46. 103.Guilford P. E-cadherin downregulation in cancer: fuel on the fire? Mol Med Today. 1999;5:172-7. 104.Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333-9. 105.Blok P, Craanen ME, Dekker W, Tytgat GN. Loss of E- cadherin expression in early gastric cancer. Histopathology. 1999;34:410-5. 106.Blok P, Craanen ME, Offerhaus GJ, Dekker W, Kuipers EJ, Meuwissen SG, Tytgat GN. Molecular alterations in early gastric carcinomas. No apparent correlation with Helicobacter pylori status. Am J Clin Pathol. 1999;111:241-7. 107.Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res. 1998;58:1021-6. 108.Jawhari AU, Noda M, Farthing MJ, Pignatelli M. Abnormal expression and function of the E-cadherin- catenin complex in gastric carcinoma cell lines. Abnormal expression and function of the E-cadherin- catenin complex in gastric carcinoma cell lines. Br J Cancer 1999;80:322-30 109.Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology. 1999;57:131-7. 110.Shiozaki H, Iihara K, Oka H, Kadowaki T, Matsui S, Gofuku J, Inoue M, Nagafuchi A, Tsukita S, Mori T. Immunohistochemical detection of alpha-catenin expression in human cancers. Am J Pathol. 1994;144:667- 74. 111.Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M, Monden T, Ito F, Monden M. Beta- catenin expression in human cancers. Am J Pathol. 1996;148:39-46. 112.Valizadeh A, Karayiannakis AJ, El-Hariry I, Kmiot W, Pignatelli M. Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am J Pathol. 1997;150:1977-84. 113.Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer. 1999;80:1046-51. 114.Efstathiou JA, Pignatelli M. Modulation of epithelial cell adhesion in gastrointestinal homeostasis. Am J Pathol. 1998;153:341-7. 115.Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KWActivation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997 21;275:1787-90. 116.Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res. 1997;57:4624-30. 117.Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res. 1998;58:1021-6. 本論文各部份均已發表且刊登於下列雜誌 1.Shun CT, Wu Ms, Lee WJ, Lin JT, Chuang SM. Relationship of mucopolysaccharide change, Helicobacter pylori infection and expression of p-53 in gastric cancer. Tzu Chi Med J. 1997;9(1):27-33. 2.Shun CT, Wu MS, Huang SP, Wang HP, Chung SM, Lin JT. Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma. Hepatogastroenterology. 2003;50(52):988-92(SCI,I.F=0.833) 3.Shun CT, Lin JT, Huang SP, Lin MT, Wu MS. Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J. of Gastroenterology. 2005;11(24): 3767-3771(SCI,I.F=3.318) 4.Shun CT, Wu MS, Lin JT, Wang HP, Houng RL, Lee WJ, Wang TH, Chuang SM. An immunohistochemical study of E- cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology. 1998 Jul-Aug;45(22):944-9(SCI, I.F=0.833) 5.Shun CT, Wu MS, Lin MT, Chang MC, Lin JT, Chuang SM. Immunohistochemical evaluation of cadherin and catenin expression in early gastric carcinomas: correlation with clinicopathologic characteristics and Helicobacter pylori infection. Oncology. 2001;60(4):339-45 (SCI,I.F=2.584 ) | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27527 | - |
| dc.description.abstract | 雖然藥物治療和衛生統計的進展降低了癌症的死亡率，但胃癌始終佔有癌症罹患和死亡的高位，甚至在遠東地區如：日本佔有第一位死亡率。所以，提高診斷率和找出相關的預後的評估因子實為很重要的課題。本論文完全利用傳統的組織化學染色和簡單的免疫組織化學染色來進行研究及評估。第一部份，我們發現胃癌的危險因子，尤其是Lauren氏腸型分類中的慢性萎縮性胃炎和具有硫性黏液的第Ⅲ型或ⅡB型的腸型化生與胃癌的發生有極密切的關係，兩者是評估胃癌發生的高危險因子；第二部份，我們探討是胃癌血管新生和抑癌基因蛋白質p53的關連性，結果我們發現血管新生因子三環類氧合酶-2在進行性胃癌或賁門癌有相當密切的關連性，但與幽門桿菌的存在與否沒有統計上的意義存在；第三部份，我們探討的是胃癌生成中細胞激素所扮演的角色，我們主要探討的是巨噬細胞遷徙抑制因子的角色，我們發現此因子在統計上與抑癌基因p53的相關性不大，但卻在腫瘤的進行和血管新生上扮演有重要的角色；最後探討的是黏著因子和胃癌生成關係，結論發現上皮性黏著因子的喪失與胃癌的生成、轉移、甚至胃癌病人的存活率都有密切的相關性存在；此外，我們亦發現不正常黏著因子複合體(Cadherin-Catenin Complex)的呈現在早期胃癌的癌發生上亦佔有一角色，更加發現這複合體的功能異常與淋巴結的轉移亦存有相當密切的關係。結論顯示胃癌是多因子的生成理論，將這些相關因子串聯起來，將是提升治療和預測胃癌病人預後的新思維。 | zh_TW |
| dc.description.abstract | Despite its decline in incidence of cancer death, gastric cancer remains the second most frequent cancer in the world and even the leading cause of death in the Far East, such as Japan. So how to improve the diagnosis and find the prognosis associated factors become an important issue in this field. In this research, we made use of classical histochemical methods and simple immunohistochemical methods. In the first part, we found the early risk factor of gastric cancer especially the Lauren’s intestinal type: chronic atrophic gastritis and the typeⅢ/ⅡB intestinal metaplasia with sulfur mucopolysaccharide change which also have correlated with the mutation of oncosuppressor gene p53. The second part of this paper, we discussed the factors associated with angiogenesis and their relationship with the oncosuppressor protein p53. We find that the close related angiogenetic factor, cyclooxygenase-2 (Cox-2), has high association with the p53 in gastric cancer, especially in advanced gastric cancer and cardiac type but not associated with Helicobacter pylori statistically. The 3rd part in this research, we discussed the role of cytokine in the gastric carcinogenesis. We focused on the macrophage migration inhibitor factor (MIF). It revealed that the macrophage migration inhibitor factor had no statistically significance with p53 but it played an important role in gastric cancer progression and neovasculization (angiogenesis with carcinogenesis). Finally we discussed the change of adhesion molecular in the gastric carcinogenesis. It showed the loss of E-cadherin in gastric cancer had close relationship with the gastric cancer formation, metastasis and even the survival rate of the patients. Furthermore, the abnormal expression of E-cadherin–catenin complex occurred frequency in gastric carcinogenesis especially at the early stage of diffuse type gastric cancer. In addition, lymph node metastasis had close relation to the dysfunction of this system. In conclusion, gastric carcinogenesis was multifactorial and how to link those factors will give us a new thinking process in treating and predicting the outcome of those types of patients. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-12T18:08:25Z (GMT). No. of bitstreams: 1 ntu-96-D86444002-1.pdf: 3438445 bytes, checksum: 96d533e03b9a0d14d6cc18a25efe121c (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 目 錄
口試委員會審定…………………………………………………………i 誌謝…………………………………………………………………… ii 中文摘要………………………………………………………………iii 英文摘要……………………………………………………………… iv I.緒論……………………………………………………………………1 II.本文 Part I.癌前期，早期胃癌和進行性胃癌的黏液和p53表現的變化…3 Part II.胃癌血管新生的探討 I.胃癌中三環類氧合酶-2與p53聚集的關連性……………………… 7 II.巨噬細胞遷徙抑制因子和血管新生的關係………………………12 Part III. 黏著因子與胃癌的關連性 I.上皮性黏著因子與胃癌的相關性………………………………… 17 II.免疫組織染色評估早期胃癌的黏著因子系統的相關性…………21 III.參考文獻………………………………………………………… 26 IV.附表…………………………………………………………………41 III.附圖……………………………………………………………… 51 | |
| dc.language.iso | zh-TW | |
| dc.subject | 黏多醣 | zh_TW |
| dc.subject | p53蛋白 | zh_TW |
| dc.subject | 胃癌 | zh_TW |
| dc.subject | 黏著因子複合體 | zh_TW |
| dc.subject | 上皮性黏著因子 | zh_TW |
| dc.subject | 巨噬細胞遷徙抑制因子 | zh_TW |
| dc.subject | 三環類氧合酶 | zh_TW |
| dc.subject | gastric cancer (GC) | en |
| dc.subject | cadherin-catenin complex | en |
| dc.subject | E-cadherin | en |
| dc.subject | macrophage migration inhibitor factor (MIF) | en |
| dc.subject | cyclooxygenase-2 (Cox-2) | en |
| dc.subject | P-53 | en |
| dc.subject | mucopolysaccharide | en |
| dc.title | 胃癌之黏多醣、血管新生及黏著因子的組織化學和免疫組織化學研究 | zh_TW |
| dc.title | The Histochemical and Immunohistochemical Study of Mucopolysaccharide, Angiogenesis and Adhesion Molecule in Gastric cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 莊壽洺(Sou-Ming Chuang),方中民(John M. Fong),賴義雄(Yih-Shyong Lai),郭宗禮(Tsung-Li Kuo) | |
| dc.subject.keyword | 胃癌,黏多醣,p53蛋白,三環類氧合酶,-2,巨噬細胞遷徙抑制因子,上皮性黏著因子,黏著因子複合體, | zh_TW |
| dc.subject.keyword | gastric cancer (GC),mucopolysaccharide,P-53,cyclooxygenase-2 (Cox-2),macrophage migration inhibitor factor (MIF),E-cadherin,cadherin-catenin complex, | en |
| dc.relation.page | 53 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-12-13 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| 顯示於系所單位： | 病理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 3.36 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。